Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CUC Inc. (9158.T)
Minato-Ku, JP
CUC Inc. delivers a diverse range of healthcare provisions across Japan, throughout Asia, and globally. Their services cover critical areas like inpatient hospital care, specialized dialysis treatments, visiting nurse programs, and home hospice support. Beyond direct patient care, the company also offers essential management assistance to healthcare organizations and provides expert healthcare consulting. Founded in 2014, CUC Inc. is headquartered in Minato-Ku, Japan, and operates as an affiliate of M3 Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -15.93% | -19.42% | -16.02% | -8.38% | -26.52% | -4.43% | -28.41% | -83.13% | -83.13% | -83.13% | -83.13% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+15.5% ★ Q1'26: +13.6% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%-8.8% Q1'26: +293.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%-0.7% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+6.7% Q1'26: +7.5% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+3.1% Q1'26: +3.6% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×6.17× Q1'26: 5.50× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 2 Rev. Ana. 2 EPS Ana. |
Mar 2028 3 Rev. Ana. 3 EPS Ana. |
Mar 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
33.03B
est: 33.09B (-0.2%)
|
47.04B
est: 47.43B (-0.8%)
|
55.08B
55.00B – 55.15B
+16.1% YoY
|
61.28B
60.00B – 62.55B
+11.3% YoY
|
69.31B
69.15B – 69.46B
+13.1% YoY
|
78.16B
76.53B – 79.79B
+12.8% YoY
|
| EBITDA |
5.52B
est: 5.45B (+1.4%)
|
8.08B
est: 7.81B (+3.5%)
|
9.06B
9.05B – 9.08B
+16.1% YoY
|
10.08B
9.87B – 10.29B
+11.3% YoY
|
11.41B
11.38B – 11.43B
+13.1% YoY
|
12.86B
12.60B – 13.13B
+12.8% YoY
|
| EBIT |
3.72B
est: 3.87B (-4.0%)
|
4.79B
est: 5.55B (-13.7%)
|
6.45B
6.44B – 6.45B
+16.1% YoY
|
7.17B
7.02B – 7.32B
+11.3% YoY
|
8.11B
8.09B – 8.13B
+13.1% YoY
|
9.15B
8.96B – 9.34B
+12.8% YoY
|
| Net Income |
2.60B
est: 2.08B (+24.5%)
|
3.13B
est: 3.10B (+0.9%)
|
2.70B
2.60B – 2.79B
-13.2% YoY
|
2.78B
2.60B – 2.96B
+3.2% YoY
|
3.94B
2.24B – 4.22B
+41.8% YoY
|
3.30B
3.21B – 3.39B
-16.3% YoY
|
| SGA |
9.83B
est: 8.75B (+12.3%)
|
14.34B
est: 12.55B (+14.3%)
|
14.57B
14.55B – 14.59B
+16.1% YoY
|
16.21B
15.87B – 16.55B
+11.3% YoY
|
18.33B
18.29B – 18.38B
+13.1% YoY
|
20.68B
20.25B – 21.11B
+12.8% YoY
|
| EPS |
93.98
est: 71.10 (+32.2%)
|
106.80
est: 105.88 (+0.9%)
|
91.94
88.70 – 95.17
-13.2% YoY
|
94.84
88.70 – 100.97
+3.2% YoY
|
115.64
76.25 – 143.99
+21.9% YoY
|
112.57
109.52 – 115.62
-2.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap Value ETF DISV | 0.00% | 91.3K | 0.42% |
| 2 | Avantis International Small Cap Value ETF AVDV | 0.00% | 186.1K | 0.36% |
| 3 | Dimensional - International Small Cap ETF DFIS | 0.00% | 54.8K | 0.39% |
| 4 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 2.5K | 0.30% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 30.5K | 0.28% |
| 6 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.00% | 2.1K | 0.39% |
| 7 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 3.0K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aya Ito | Executive Officer & President of Sophia Medi Co., Ltd. | — | male |
| Keita Hamaguchi | Founder, CEO & Representative Director | — | male |
| Takamichi Tanabe | COO & Director | — | male |
| Toshio Matsuura | CHRO & Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9158.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
